Please login to the form below
rituximab
This page shows the latest rituximab news and features for those working in and with pharma, biotech and healthcare.
Amgen’s Riabni combination granted FDA approval for rheumatoid arthritis
Amgen’s Riabni (rituximab-arrx), in combination with methotrexate, has been approved by the US Food and Drug Administration (FDA) for adults with moderate to severely active rheumatoid arthritis (RA). ... Riabni is a cytolytic antibody that was
Latest news
-
Pfizer's 2021 revenue predictions soar to $82bn
Pfizer’s biosimilars business grew by 34% to $575m, driven by the launches of Ruxience (rituximab), Zirabev (bevacizumab) and Trazimera (trastuzumab), as well as continued growth from Retacrit (epoetin) in the
-
Orphan status in Europe for lymphoma drug Zynlonta
About 60% of patients with DLBCL are cured with regimens such as rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone (R-CHOP), however, most patients who relapse or do not respond to therapy
-
Roche’s diagnostic business sales offer a bright spot in Q4
treatments Herceptin (trastuzumab), Avastin (bevacizumab) and Rituxan (rituximab).
-
Pfizer CEO says COVID-19 vaccine efficacy data could come ‘soon’
Global revenues for its biosimilar also reach $424m, up 80% operationally, driven mostly by recent oncology launches of Ruxience (rituximab), Zirabev (bevacizumab) and Trazimera (trastuzumab) in the US and other global
-
NICE recommends Roche’s Polivy for B-cell lymphoma
drug conjugate Polivy in combination with Rituxan (rituximab) and bendamustine for the treatment of diffuse large B-cell lymphoma (DLBCL).
More from news
Approximately 9 fully matching, plus 154 partially matching documents found.
Latest Intelligence
-
Will biosimilars ever catch on in the US?
The UK has been especially proactive with biosimilars. Three biologics there – infliximab, rituximab and etanercept –underwent an average price reduction of 40% when their biosimilars were introduced. ... After the launch of the biosimilar for
-
The sound of silence puts the squeeze on generics and biosimilars
drugs - from Adalimumab to Rituximab - go off-patent and boost savings across eight European nations to 33.4bn over the next three years.
-
2016: The year when deal-makers took stock?
Canada for biosimilar versions of Rituxan (rituximab) and Herceptin (trastuzumab).
-
Deal Watch December 2016
Sanofi's payments to JHL, the Taiwanese manufacturer of a rituximab biosimilar, total $101m upfront for the China market alone; 30% of the headline figure.
-
Deal Watch November 2016
By destroying B cells, rituximab is used to treat diseases characterised by excessive numbers of B cells, overactive B cells or dysfunctional B cells including many lymphomas, leukaemias, transplant rejection and ... In May this year Sandoz announced
More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.
Latest appointments
-
ImmunoGen hires VP product strategy
His previous business experience includes several oncology-related positions at Biogen Idec, including team leader for Rituxan (rituximab), as well as commercial positions at Amgen,.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Covid-19: how is it affecting prescribing patterns?
From March 2019, use of on-patent Etanercept, Adalimumab and Rituximab went down, while the Adalimumab biosimilar went up and so did Etanercept and Rituximab biosimilars.
-
The Biosimilar Challenge
Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).
-
Biosimilars: Getting the flock to market
The greatest attraction, naturally, is high-revenue anti-TNF agents like MabThera (rituximab) and Humira (adalimumab), for many years the world's most valuable drug.
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- Eli Lilly to make bebtelovimab commercially available to US states from August
- ONS records a continued fall in UK COVID-19 infections
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Biogen and Eisai share latest lecanemab results for the treatment of Alzheimer's disease
- Engaging KOLs and Gaining Insights in Pharma's New Normal
- That ‘don’t’ impress me much
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
PMHub
Accession
Accession was a born from a passion and a vision. A passion to harness the power of market access to...
Latest intelligence
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
- How the Royal Society’s EiR programme can help to drive UK innovation
- ...
